文献速递胰腺与胆道疾病消化道肿瘤与早癌肝病

基于液体活检的蛋白质生物标志物用于胆管癌的风险预测、早期诊断和预后判断

Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma.
PubMed 文献 · J Hepatol · 2023-03-01

研究在血清细胞外囊泡(EV)中寻找蛋白质生物标志物,纳入孤立性PSC、合并PSC-CCA、随访中发生CCA的PSC、非PSC病因CCA、肝细胞癌及健康人共6组,经质谱发现、ELISA验证。机器学习模型CRP/FIBRINOGEN/FRIL诊断PSC相关局限性CCA的AUC为0.947、OR为36.9,CRP/FRIL诊断局限性泛CCA的AUC为0.941、OR为89.4。

要点

  • CRP/FIBRINOGEN/FRIL诊断PSC相关局限性CCA vs 孤立性PSC的AUC=0.947、OR=36.9。
  • CRP/FRIL诊断局限性泛CCA的AUC=0.941、OR=89.4。
  • EV标志物COMP/GNAI2/CFAI与生存负相关,ACTN1/MYCT1/PF4V与生存正相关。

核心结论

  • 血清EV中含有可用于CCA预测、早期诊断和预后判断的蛋白质生物标志物,可通过全血清检测。
  • 这些标志物代表一种肿瘤细胞来源的液体活检工具,可用于个性化医疗。

研究设计与样本

  • 研究纳入孤立性PSC(n=45)、合并PSC-CCA(n=44)、随访中发生CCA的PSC(PSC to CCA;n=25)、非PSC病因CCA(n=56)、肝细胞癌(n=34)及健康人(n=56)。
  • 对血清EV进行质谱表征以发现诊断生物标志物,并用ELISA在全血清中交叉验证。
  • 在CCA肿瘤单细胞水平评估标志物表达,并研究CCA的预后EV生物标志物。

主要发现

  • 机器学习算法得出CRP/FIBRINOGEN/FRIL用于诊断PSC-CCA(局限性病变[LD])vs 孤立性PSC,AUC=0.947、OR=36.9,联合碳水化合物抗原19-9时优于单用碳水化合物抗原19-9。
  • CRP/PIGR/VWF用于诊断LD非PSC CCA vs 健康人,AUC=0.992、OR=387.5。
  • CRP/FRIL准确诊断LD泛CCA,AUC=0.941、OR=89.4。
  • CRP/FIBRINOGEN/FRIL/PIGR水平在PSC患者出现恶性肿瘤临床证据前具有预测CCA发生的能力。
  • 多变量分析显示EV预后标志物COMP/GNAI2/CFAI与患者生存负相关,ACTN1/MYCT1/PF4V与患者生存正相关。

关键数值与推荐

  • CRP/FIBRINOGEN/FRIL诊断PSC-CCA(LD)vs 孤立性PSC:AUC=0.947、OR=36.9。
  • CRP/PIGR/VWF诊断LD非PSC CCA vs 健康人:AUC=0.992、OR=387.5。
  • CRP/FRIL诊断LD泛CCA:AUC=0.941、OR=89.4。

临床怎么用

  • 作者认为这些新型液体活检工具可能实现散发性CCA的简便无创诊断。
  • 作者认为可能识别CCA发生风险较高的PSC患者。
  • 作者认为可能为高危人群(如PSC)建立具成本效益的CCA早期检测监测方案。
  • 作者认为可能对CCA患者进行预后分层。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Cholangiocarcinoma (CCA), heterogeneous biliary tumours with dismal prognosis, lacks accurate early diagnostic methods especially important for individuals at high-risk (i.e. those with primary sclerosing cholangitis [PSC]). Here, we searched for protein biomarkers in serum extracellular vesicles (EVs). METHODS: EVs from patients with isolated PSC (n = 45), concomitant PSC-CCA (n = 44), PSC who developed CCA during follow-up (PSC to CCA; n = 25), CCAs from non-PSC aetiology (n = 56), and hepatocellular carcinoma (n = 34) and healthy individuals (n = 56) were characterised by mass spectrometry. Diagnostic biomarkers for PSC-CCA, non-PSC CCA, or CCAs regardless of aetiology (Pan-CCAs) were defined and validated by ELISA. Their expression was evaluated in CCA tumours at a single-cell level. Prognostic EV biomarkers for CCA were investigated. RESULTS: High-throughput proteomics of EVs identified diagnostic biomarkers for PSC-CCA, non-PSC CCA, or Pan-CCA, and for the differential diagnosis of intrahepatic CCA and hepatocellular carcinoma, which were cross-validated by ELISA using total serum. Machine learning-based algorithms disclosed CRP/FIBRINOGEN/FRIL for the diagnosis of PSC-CCA (local disease [LD]) vs. isolated PSC (AUC = 0.947; odds ratio [OR] =36.9) and, combined with carbohydrate antigen 19-9, overpowers carbohydrate antigen 19-9 alone. CRP/PIGR/VWF allowed the diagnosis of LD non-PSC CCAs vs. healthy individuals (AUC = 0.992; OR = 387.5). It is noteworthy that CRP/FRIL accurately diagnosed LD Pan-CCA (AUC = 0.941; OR = 89.4). Levels of CRP/FIBRINOGEN/FRIL/PIGR showed predictive capacity for CCA development in PSC before clinical evidence of malignancy. Multi-organ transcriptomic analysis revealed that serum EV biomarkers were mostly expressed in hepatobiliary tissues, and single-cell RNA sequencing and immunofluorescence analysis of CCA tumours showed their presence mainly in malignant cholangiocytes. Multivariable analysis unveiled EV prognostic biomarkers, with COMP/GNAI2/CFAI and ACTN1/MYCT1/PF4V associated negatively and positively with patients' survival, respectively. CONCLUSIONS: Serum EVs contain protein biomarkers for the prediction, early diagnosis, and prognostication of CCA that are detectable using total serum, representing a tumour cell-derived liquid biopsy tool for personalised medicine. IMPACT AND IMPLICATIONS: The accuracy of current imaging tests and circulating tumour biomarkers for cholangiocarcinoma (CCA) diagnosis is far from satisfactory. Most CCAs are considered sporadic, although up to 20% of patients with primary sclerosing cholangitis (PSC) develop CCA during their lifetime, constituting a major cause of PSC-related death. This international study has proposed protein-based and aetiology-related logistic models with predictive, diagnostic, or prognostic capacities by combining two to four circulating protein biomarkers, moving a step forward into personalised medicine. These novel liquid biopsy tools may allow the (i) easy and non-invasive diagnosis of sporadic CCAs, (ii) identification of patients with PSC with higher risk for CCA development, (iii) establishment of cost-effective surveillance programmes for the early detection of CCA in high-risk populations (e.g. PSC), and (iv) prognostic stratification of patients with CCA, which, altogether, may increase the number of cases eligible for potentially curative options or to receive more successful treatments, decreasing CCA-related mortality.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Lapitz A, Azkargorta M, Milkiewicz P, et al. Liquid biopsy-based protein biomarkers for risk prediction, early diagnosis, and prognostication of cholangiocarcinoma. J Hepatol. 2023. PMID: 36868481. doi:10.1016/j.jhep.2023.02.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。